About Prof. Tao Rong
Prof. Tao Rong (陶荣) is the Director of the Lymphoma Department at Fudan University Shanghai Cancer Center (FUSCC) — one of the few dedicated lymphoma department directors in China, reflecting the scale and specialization of FUSCC's lymphoma program. Prof. Tao's clinical focus centers on three of the most challenging lymphoma subtypes: NK/T-cell lymphoma, peripheral T-cell lymphoma (PTCL), and high-risk diffuse large B-cell lymphoma (DLBCL). His participation in research that has informed NCCN (National Comprehensive Cancer Network) guidelines places him among a select group of Chinese lymphoma specialists whose work has achieved international recognition.
T-cell and NK/T-cell lymphomas are biologically distinct from B-cell lymphomas, more common in Asia than in Western populations, and historically associated with poorer outcomes due to resistance to standard B-cell lymphoma protocols. Prof. Tao's subspecialty focus on these aggressive subtypes — combined with his expertise in high-risk DLBCL — makes him one of the most relevant specialists in China for international patients from the Middle East, Southeast Asia, and Central Asia, where T-cell and NK/T-cell lymphomas have higher incidence.
Clinical Expertise
- NK/T-cell lymphoma (nasal type) — the most common T-cell/NK-cell lymphoma in Asia; L-asparaginase-based regimens (SMILE, AspaMetDex, P-GemOx) are the cornerstone of treatment; PD-1 inhibitors (sintilimab, pembrolizumab) show significant activity in relapsed disease
- Peripheral T-cell lymphoma (PTCL) — a heterogeneous group including PTCL-NOS, angioimmunoblastic T-cell lymphoma (AITL), and ALK-positive/negative anaplastic large cell lymphoma (ALCL); CHOP-based induction with consolidative ASCT for eligible patients
- High-risk DLBCL — double-hit/triple-hit lymphoma, IPI high-risk disease, and primary refractory DLBCL; intensified induction strategies, CAR-T cell therapy, and clinical trial access
- NCCN guideline-informed treatment — participation in research that has shaped international lymphoma treatment standards, ensuring patients receive evidence-based care aligned with global best practices
- Novel agents for T-cell lymphoma — brentuximab vedotin (for CD30+ PTCL and ALCL), chidamide (a histone deacetylase inhibitor approved in China for relapsed PTCL), and PD-1 inhibitors
- CAR-T cell therapy for aggressive lymphoma — patient selection and coordination for eligible patients with relapsed/refractory high-risk DLBCL
- Multidisciplinary lymphoma management — leading FUSCC's dedicated lymphoma department with integrated pathology, radiology, and oncology expertise
Why Prof. Tao Rong?
T-cell and NK/T-cell lymphomas are diseases where subspecialty expertise is particularly critical. These subtypes do not respond to rituximab (which targets CD20, a B-cell marker), meaning that standard R-CHOP — the backbone of B-cell lymphoma treatment — is ineffective. Patients who receive R-CHOP for a T-cell lymphoma are not just receiving suboptimal therapy; they are receiving the wrong therapy entirely. Accurate subtype diagnosis and access to a specialist with T-cell lymphoma experience are therefore prerequisites for effective treatment.
NK/T-cell lymphoma has a particularly high incidence in East and Southeast Asia, and L-asparaginase-based regimens — which are the standard of care — require careful dosing and toxicity management that is best handled by an experienced specialist. Prof. Tao's focused experience with these regimens, combined with his access to PD-1 inhibitors and novel agents for relapsed disease, provides a comprehensive treatment pathway for patients with this diagnosis.
His participation in NCCN-referenced research also signals a level of academic engagement that translates directly into patient care: Prof. Tao is not just applying existing guidelines but contributing to their development, which means his patients benefit from the most current evidence and emerging treatment approaches.
Hospital: Fudan University Shanghai Cancer Center (FUSCC)
FUSCC is China's premier dedicated cancer hospital, with a lymphoma department that is among the most comprehensive and highest-volume in the country. The department's dedicated structure — with subspecialty expertise in B-cell lymphomas, T-cell lymphomas, CNS lymphoma, and lymphoma pathology — ensures that patients receive care from specialists rather than generalists. FUSCC's active clinical trials program provides access to investigational agents not yet widely available, and its pathology department provides the molecular and genomic testing infrastructure essential for precise lymphoma subtyping.
About T-Cell & NK/T-Cell Lymphoma
T-cell and NK/T-cell lymphomas account for approximately 10–15% of all non-Hodgkin lymphomas globally, but up to 25–30% in Asia — making them disproportionately relevant for patients from the Middle East, Southeast Asia, East Asia, and Central Asia. Key facts:
- NK/T-cell lymphoma (nasal type): strongly associated with EBV infection; presents with nasal obstruction, facial swelling, or midline destructive lesions; PET-CT is essential for staging; L-asparaginase-based regimens achieve CR rates of 60–80% in early-stage disease
- PTCL-NOS: the most common PTCL subtype; heterogeneous biology; 5-year survival of 30–40% with CHOP-based therapy; consolidative ASCT improves outcomes in first remission
- AITL (angioimmunoblastic T-cell lymphoma): associated with TET2, DNMT3A, and RHOA mutations; IDH2 inhibitors and PI3K inhibitors show activity; hypomethylating agents (azacitidine) are being explored
- ALK+ ALCL: the most favorable PTCL subtype; 5-year survival of 70–80% with CHOP; ALK inhibitors (crizotinib, alectinib) show activity in relapsed disease
- Chidamide: a Chinese-developed HDAC inhibitor approved for relapsed/refractory PTCL; response rate of ~28% as monotherapy, higher in combinations
- Brentuximab vedotin: approved for CD30+ PTCL (including ALCL) in combination with CHP (cyclophosphamide, doxorubicin, prednisone) as first-line therapy
What to Prepare Before Your Consultation
To enable Prof. Tao's team to conduct a thorough remote case review, international patients should prepare:
- Pathology report with full IHC panel including T-cell markers (CD3, CD4, CD8, CD56, TIA-1, granzyme B, CD30, ALK, EBER ISH for EBV)
- TCR gene rearrangement studies if performed
- PET-CT scan for staging and response assessment
- Bone marrow biopsy report
- EBV DNA quantification (plasma EBV PCR) for NK/T-cell lymphoma
- LDH, beta-2 microglobulin, CBC with differential
- Complete treatment history with regimens, dates, and best response
- Current performance status and any active symptoms
How CMCS Can Help
China Medical Concierge Shanghai (CMCS) coordinates access to Prof. Tao Rong and the FUSCC lymphoma department for international patients. Our services include:
- Remote case review and pre-consultation assessment before you travel
- Priority appointment scheduling with Prof. Tao's team at FUSCC
- Full translation of pathology reports, imaging, and treatment plans
- In-hospital accompaniment by a dedicated English-speaking case manager
- Accommodation, airport transfer, and logistics coordination in Shanghai
- Post-discharge follow-up and remote consultation support after returning home
Contact us to begin your case review:
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
0 commenti